---
title: "Resistance exercise preserves lean mass during tirzepatide therapy for obesity"
id: "nature-1-resistance-exercise-to-attenuate-lean-mass-loss-during-tirzepatide-therapy-for"
canonical_url: "https://medichelpline.com/clinical-feed/nature-1-resistance-exercise-to-attenuate-lean-mass-loss-during-tirzepatide-therapy-for"
content_type: "clinical_feed_article"
specialty: "Endocrinology"
source_name: "Nature Medicine"
source_url: "https://www.nature.com/articles/s41591-026-04752-5"
published_at: "2026-11-09T12:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Resistance exercise preserves lean mass during tirzepatide therapy for obesity
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/nature-1-resistance-exercise-to-attenuate-lean-mass-loss-during-tirzepatide-therapy-for
- **Specialty:** [Endocrinology](https://medichelpline.com/clinical-feed/endocrinology.md)
- **Primary Source:** Nature Medicine
- **Source URL:** [Original Journal Publication](https://www.nature.com/articles/s41591-026-04752-5)
- **Published At:** 2026-11-09T12:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- Two-arm randomized controlled trial evaluated whether adding **resistance exercise** (REx) to weekly **tirzepatide** (T) treatment attenuates loss of **lean soft tissue mass** in adults with overweight or obesity. - One hundred twenty adults were treated with tirzepatide and randomized to thrice-weekly supervised resistance training or usual activities for 40 weeks; co-primary endpoints were change in total fat mass and total lean soft tissue mass measured by **DXA**. - Tirzepatide dosing was generally tolerated, with most participants able to escalate to 15 mg weekly, and the study team reported no safety signals that prevented titration. - Adherence to the resistance exercise program was high (reported as 91%), indicating acceptability of the intervention during pharmacotherapy. - Weight loss was large and similar between groups (T = −22.61 kg; T+REx = −22.28 kg; P = 0.694), and loss of total fat mass did not differ significantly between groups (P = 0.700; between-group difference −0.77 kg; 95% CI −2.14 to 0.60 kg). - The REx arm showed smaller losses of total lean soft tissue mass (T = −4.67 kg; T+REx = −3.57 kg; P < 0.001), with a between-group difference of 1.09 kg (95% CI 0.43–1.75 kg) favoring the combined intervention. - Appendicular lean soft tissue mass loss was reduced with resistance training (T = −3.55 kg; T+REx = −2.92 kg; P < 0.001), indicating regional preservation of limb muscle mass. - Muscle strength findings diverged: bench press, lat pulldown and knee extension strength fell with tirzepatide alone (bench −4.09 kg; lat pulldown −4.42 kg; knee extension −4.42 kg) but increased in the T+REx group (+4.68 kg, +8.58 kg, +5.88 kg respectively); all comparisons versus tirzepatide had P < 0.001. - Secondary cardiovascular risk factor outcomes were collected but are reported only as part of the trial results; the provided excerpt did not give further numerical detail on these endpoints. - Trial registration: Australian New Zealand Clinical Trials Registry ACTRN12623001236684. The provided text did not include full methods, participant baseline characteristics, adverse event tables, or detailed statistical analysis plans.
## Clinical Analysis & Structured Key Points
## Your privacy, your choice We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media, as well as to allow video information to be shared for both marketing, analytics and editorial purposes. By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection. See our [privacy policy](https://www.nature.com/info/privacy) for more information on the use of your personal data. Manage preferences for further information and to change your choices. Accept all cookies Reject optional cookies [Skip to main content](https://www.nature.com/articles/s41591-026-04752-5#content) Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript. Advertisement [ ![Nature Medicine](https://media.springernature.com/full/nature-cms/uploads/product/nm/header-95e59e63930e5d6009bad2c23a42ab2d.svg) ](https://www.nature.com/nm) * [ View all journals ](https://www.nature.com/siteindex) * [ Saved research ](https://www.nature.com/saved-research) * [ Search ](javascript:;) ## Search Search articles by subject, keyword or author Show results from All journals This journal Search [ Advanced search ](https://www.nature.com/search/advanced) ### Quick links * [Explore articles by subject](https://www.nature.com/subjects) * [Find a job](https://www.nature.com/naturecareers) * [Guide to authors](https://www.nature.com/authors/index.html) * [Editorial policies](https://www.nature.com/authors/editorial_policies/) * [Log in](https://idp.nature.com/auth/personal/springernature?redirect_uri=https://www.nature.com/articles/s41591-026-04752-5) * [ Content Explore content ](javascript:;) ## Explore content * [ Research articles ](https://www.nature.com/nm/research-articles) * [ Reviews & Analysis ](https://www.nature.com/nm/reviews-and-analysis) * [ News & Comment ](https://www.nature.com/nm/news-and-comment) * [ Podcasts ](https://www.nature.com/nm/podcast) * [ Current issue ](https://www.nature.com/nm/current-issue) * [ Collections ](https://www.nature.com/nm/collections) * [Follow us on Facebook ](https://www.facebook.com/Nature-Medicine-193691346949/) * [Follow us on X ](https://twitter.com/naturemedicine) * [Sign up for alerts ](https://journal-alerts.springernature.com/subscribe?journal_id=41591) * [ RSS feed ](https://www.nature.com/nm.rss) * [ About the journal ](javascript:;) ## About the journal * [ Aims & Scope ](https://www.nature.com/nm/aims) * [ Journal Information ](https://www.nature.com/nm/journal-information) * [ Editors ](https://www.nature.com/nm/editors) * [ Journal Metrics ](https://www.nature.com/nm/journal-impact) * [ Research Cross-Journal Editorial Team ](https://www.nature.com/nm/research-cross-journal-editorial-team) * [ Reviews Cross-Journal Editorial Team ](https://www.nature.com/nm/reviews-cross-journal-editorial-team) * [ Statistical Advisory Panel ](https://www.nature.com/nm/statistics-advisory-panel) * [ Our publishing models ](https://www.nature.com/nm/our-publishing-models) * [ Editorial Values Statement ](https://www.nature.com/nm/editorial-values-statement) * [ Editorial Policies ](https://www.nature.com/nm/editorial-policies) * [ Content Types ](https://www.nature.com/nm/content) * [ Web Feeds ](https://www.nature.com/nm/web-feeds) * [ Contact ](https://www.nature.com/nm/contact) * [ Publish with us ](javascript:;) ## Publish with us * [ Submission Guidelines ](https://www.nature.com/nm/submission-guidelines) * [ For Reviewers ](https://www.nature.com/nm/for-reviewers) * [ Language editing services ](https://authorservices.springernature.com/go/sn/?utm_source=For+Authors&utm_medium=Website_Nature&utm_campaign=Platform+Experimentation+2022&utm_id=PE2022) * [Open access funding](https://www.nature.com/nm/open-access-funding) * [Submit manuscript ](https://mts-nmed.nature.com/cgi-bin/main.plex) * [ Sign up for alerts ](https://journal-alerts.springernature.com/subscribe?journal_id=41591) * [ RSS feed ](https://www.nature.com/nm.rss) 1. [nature](https://www.nature.com/) 2. [nature medicine](https://www.nature.com/nm) 3. [articles](https://www.nature.com/nm/articles?type=article) 4. article Resistance exercise to attenuate lean mass loss during tirzepatide therapy for obesity: a randomized controlled trial [ Download PDF ](https://www.nature.com/articles/s41591-026-04752-5.pdf) [ Download PDF ](https://www.nature.com/articles/s41591-026-04752-5.pdf) * Article * [Open access](https://www.springernature.com/gp/open-science/about/the-fundamentals-of-open-access-and-open-research) * Published: 09 November 2026 # Resistance exercise to attenuate lean mass loss during tirzepatide therapy for obesity: a randomized controlled trial * [Daniel J. Green](https://www.nature.com/articles/s41591-026-04752-5#auth-Daniel_J_-Green-Aff1-Aff2-Aff3) [ORCID: orcid.org/0000-0003-3226-2921](https://orcid.org/0000-0003-3226-2921)[1](https://www.nature.com/articles/s41591-026-04752-5#Aff1),[2](https://www.nature.com/articles/s41591-026-04752-5#Aff2),[3](https://www.nature.com/articles/s41591-026-04752-5#Aff3), * [Andrew Haynes](https://www.nature.com/articles/s41591-026-04752-5#auth-Andrew-Haynes-Aff1-Aff2) [ORCID: orcid.org/0000-0001-7312-8265](https://orcid.org/0000-0001-7312-8265)[1](https://www.nature.com/articles/s41591-026-04752-5#Aff1),[2](https://www.nature.com/articles/s41591-026-04752-5#Aff2), * [Destiny R. Underwood](https://www.nature.com/articles/s41591-026-04752-5#auth-Destiny_R_-Underwood-Aff1-Aff2)[1](https://www.nature.com/articles/s41591-026-04752-5#Aff1),[2](https://www.nature.com/articles/s41591-026-04752-5#Aff2), * [Evangeline R. Winterton](https://www.nature.com/articles/s41591-026-04752-5#auth-Evangeline_R_-Winterton-Aff1-Aff2)[1](https://www.nature.com/articles/s41591-026-04752-5#Aff1),[2](https://www.nature.com/articles/s41591-026-04752-5#Aff2), * [Abbey A. Green](https://www.nature.com/articles/s41591-026-04752-5#auth-Abbey_A_-Green-Aff1-Aff2)[1](https://www.nature.com/articles/s41591-026-04752-5#Aff1),[2](https://www.nature.com/articles/s41591-026-04752-5#Aff2), * [Robin M. Daly](https://www.nature.com/articles/s41591-026-04752-5#auth-Robin_M_-Daly-Aff4)[4](https://www.nature.com/articles/s41591-026-04752-5#Aff4), * [Elena S. George](https://www.nature.com/articles/s41591-026-04752-5#auth-Elena_S_-George-Aff4)[4](https://www.nature.com/articles/s41591-026-04752-5#Aff4), * [Leanne Lester](https://www.nature.com/articles/s41591-026-04752-5#auth-Leanne-Lester-Aff2-Aff5)[2](https://www.nature.com/articles/s41591-026-04752-5#Aff2),[5](https://www.nature.com/articles/s41591-026-04752-5#Aff5), * [Louise H. Naylor](https://www.nature.com/articles/s41591-026-04752-5#auth-Louise_H_-Naylor-Aff1-Aff2)[1](https://www.nature.com/articles/s41591-026-04752-5#Aff1),[2](https://www.nature.com/articles/s41591-026-04752-5#Aff2), * [Graham S. Hillis](https://www.nature.com/articles/s41591-026-04752-5#auth-Graham_S_-Hillis-Aff6-Aff7)[6](https://www.nature.com/articles/s41591-026-04752-5#Aff6),[7](https://www.nature.com/articles/s41591-026-04752-5#Aff7), * [P. Gerry Fegan](https://www.nature.com/articles/s41591-026-04752-5#auth-P__Gerry-Fegan-Aff2-Aff8-Aff9) [ORCID: orcid.org/0000-0001-8100-6209](https://orcid.org/0000-0001-8100-6209)[2](https://www.nature.com/articles/s41591-026-04752-5#Aff2),[8](https://www.nature.com/articles/s41591-026-04752-5#Aff8),[9](https://www.nature.com/articles/s41591-026-04752-5#Aff9) & * … * [Bu B. Yeap](https://www.nature.com/articles/s41591-026-04752-5#auth-Bu_B_-Yeap-Aff2-Aff6-Aff9) [ORCID: orcid.org/0000-0002-7612-5892](https://orcid.org/0000-0002-7612-5892)[2](https://www.nature.com/articles/s41591-026-04752-5#Aff2),[6](https://www.nature.com/articles/s41591-026-04752-5#Aff6),[9](https://www.nature.com/articles/s41591-026-04752-5#Aff9) Show authors [_Nature Medicine_](https://www.nature.com/nm) (2026) [Cite this article](https://www.nature.com/articles/s41591-026-04752-5#citeas) Save article [ View saved research ](https://www.nature.com/saved-research) ## Abstract Incretin mimetics as obesity therapy induce substantial weight and fat loss but also decrease lean soft tissue mass, possibly impairing skeletal muscle function. Here, in this two-arm randomized controlled trial of adding resistance exercise (REx) to tirzepatide (T), 120 adults with overweight or obesity were treated with tirzepatide and randomized to thrice-weekly resistance exercise training or usual activities for 40 weeks. Tirzepatide was safe, and most participants tolerated up-titration to 15 mg weekly. Adherence to resistance exercise was 91%. Weight loss achieved was similar (T = −22.61 kg, T+REx = −22.28 kg, _P_ = 0.694). For primary outcomes, loss of total fat mass was similar (T = −17.19 kg, T+REx = −17.98 kg, _P_ = 0.700; between-group difference = −0.77 kg, 95% confidence interval (CI): −2.14 kg to 0.60 kg), but resistance exercise reduced loss of total lean soft tissue mass (T = −4.67 kg, T+REx = −3.57 kg, _P_ < 0.001; between-group difference = 1.09 kg, 95% CI: 0.43−1.75 kg). For related endpoints, resistance exercise reduced loss of appendicular lean soft tissue mass (T = −3.55 kg, T+REx = −2.92 kg, _P_ < 0.001). Upper and lower body muscle strength decreased with tirzepatide (bench press −4.09 kg, lat pulldown −4.42 kg, knee extension −4.42 kg) but increased with T+REx (+4.68 kg, +8.58 kg, +5.88 kg, respectively, all _P_ < 0.001 versus tirzepatide). In conclusion, resistance exercise training attenuated loss of total lean soft tissue mass, representing an effective adjunct to tirzepatide anti-obesity therapy. Australian New Zealand Clinical Trials Registry identifier: [ACTRN12623001236684](http://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=385806). ### Explore related subjects Discover the latest articles and news in related subjects. * [Lifestyle modification](https://www.nature.com/subjects/lifestyle-modification) * [Obesity](https://www.nature.com/subjects/obesity) * [Prognostic markers](https://www.nature.com/subjects/prognostic-markers) * [Sarcopenia Assessment and Nutritional Interventions in Older Adults](https://www.nature.com/subjects/sarcopenia-assessment-and-nutritional-interventions-in-older-adults) ## Main The worldwide prevalence of obesity is a major public health challenge[1](https://www.nature.com/articles/s41591-026-04752-5#ref-CR1 "NCD Risk Factor Collaboration \(NCD-RisC\).Obesity rise plateaus in developed nations and accelerates in developing nations. Nature 653, 510–518 \(2026\)."). This is amplified by the role of excess adiposity as a gateway to multiple cardiometabolic complications[2](https://www.nature.com/articles/s41591-026-04752-5#ref-CR2 "Valenzuela, P. L. et al. Obesity and the risk of cardiometabolic diseases. Nat. Rev. Cardiol. 20, 475–494 \(2023\)."). Mimetics of endogenous nutrient-stimulated hormones released from the gut (‘incretins’) represent a novel strategy for the management of obesity[3](https://www.nature.com/articles/s41591-026-04752-5#ref-CR3 "Wilding, J. P. et al. Once-weekly semaglutide in adults with overweight or obesity. N. Engl. J. Med. 384, 989–1002 \(2021\)."),[4](https://www.nature.com/articles/s41591-026-04752-5#ref-CR4 "Jastreboff, A. M. et al. Tirzepatide once weekly for the treatment of obesity. N. Engl. J. Med. 387, 205–216 \(2022\)."). Unsurprisingly, their use has accelerated, such that, in a sample of US adults, 11% reported taking these weight loss medications in 2026 (ref. [5](https://www.nature.com/articles/s41591-026-04752-5#ref-CR5 "Witters, D. In U.S., GLP-1 usage reaches new high https://news.gallup.com/poll/712157/glp-usage-reaches-new-high.aspx \(2026\).")), with expenditure on this drug class predicted to increase 10-fold from 2023 to 2033 (ref. [6](https://www.nature.com/articles/s41591-026-04752-5#ref-CR6 "Recasens-Alvarez, C., Heap, G. & Green, G. The evolution of the obesity drug market. Nat. Rev. Drug Discov. 24, 902–903 \(2025\).")). The scale of the underlying condition and this rapid uptake of anti-obesity therapies prompt careful consideration of their benefits but also their immediate and potential longer-term risks[7](https://www.nature.com/articles/s41591-026-04752-5#ref-CR7 "Moiz, A. et al. Efficacy and safety of glucagon-like peptide-1 receptor agonists for weight loss among adults without diabetes: a systematic review of randomized controlled trials. Ann. Intern. Med. 178, 199–217 \(2025\)."). Studies of incretin mimetics in adults with obesity have reported total body weight reductions in the range of 15−24%[3](https://www.nature.com/articles/s41591-026-04752-5#ref-CR3 "Wilding, J. P. et al. Once-weekly semaglutide in adults with overweight or obesity. N. Engl. J. Med. 384, 989–1002 \(2021\)."),[4](https://www.nature.com/articles/s41591-026-04752-5#ref-CR4 "Jastreboff, A. M. et al. Tirzepatide once weekly for the treatment of obesity. N. Engl. J. Med. 387, 205–216 \(2022\)."),[8](https://www.nature.com/articles/s41591-026-04752-5#ref-CR8 "Jastreboff, A. M. et al. Triple-hormone-receptor agonist retatrutide for obesity—a phase 2 trial. N. Engl. J. Med. 389, 514–526 \(2023\)."), which is accompanied by 25−34% reductions in total body fat[3](https://www.nature.com/articles/s41591-026-04752-5#ref-CR3 "Wilding, J. P. et al. Once-weekly semaglutide in adults with overweight or obesity. N. Engl. J. Med. 384, 989–1002 \(2021\)."),[4](https://www.nature.com/articles/s41591-026-04752-5#ref-CR4 "Jastreboff, A. M. et al. Tirzepatide once weekly for the treatment of obesity. N. Engl. J. Med. 387, 205–216 \(2022\)."),[9](https://www.nature.com/articles/s41591-026-04752-5#ref-CR9 "Locatelli, J. C. et al. Incretin-based weight loss pharmacotherapy: can resistance exercise optimize changes in body composition? Diabetes Care 47, 1718–1730 \(2024\).") and even greater reductions in visceral adipose tissue and in fat accumulated in ectopic depots such as the liver[10](https://www.nature.com/articles/s41591-026-04752-5#ref-CR10 "Gastaldelli, A. et al. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes \(SURPASS-3 MRI\): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol. 10, 393–406 \(2022\)."). However, a focus on weight and fat loss masks impacts of these therapies on lean soft tissue mass, which includes skeletal muscle mass[11](https://www.nature.com/articles/s41591-026-04752-5#ref-CR11 "Conte, C., Hall, K. D. & Klein, S. Is weight loss–induced muscle mass loss clinically relevant? JAMA 332, 9–10 \(2024\)."). In studies assessing body composition using dual energy X-ray absorptiometry (DXA), incretin mimetic therapy for obesity resulted in 11−14% losses in total body lean soft tissue mass[3](https://www.nature.com/articles/s41591-026-04752-5#ref-CR3 "Wilding, J. P. et al. Once-weekly semaglutide in adults with overweight or obesity. N. Engl. J. Med. 384, 989–1002 \(2021\)."),[4](https://www.nature.com/articles/s41591-026-04752-5#ref-CR4 "Jastreboff, A. M. et al. Tirzepatide once weekly for the treatment of obesity. N. Engl. J. Med. 387, 205–216 \(2022\)."),[9](https://www.nature.com/articles/s41591-026-04752-5#ref-CR9 "Locatelli, J. C. et al. Incretin-based weight loss pharmacotherapy: can resistance exercise optimize changes in body composition? Diabetes Care 47, 1718–1730 \(2024\)."). Skeletal muscle volume, assessed using magnetic resonance imaging (MRI), is also reduced by incretin mimetics, albeit with some reduction in muscle fat content[12](https://www.nature.com/articles/s41591-026-04752-5#ref-CR12 "Sattar, N. et al. Tirzepatide and muscle composition changes in people with type 2 diabetes \(SURPASS-3 MRI\): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial. Lancet Diabetes Endocrinol. 13, 482–493 \(2025\)."). That study did not assess the timecourse of body composition change or the effect of incretin mimetics on muscle function. Loss of skeletal muscle mass predisposes to sarcopenia and frailty in older adults, giving rise to concerns over potential risks posed by muscle loss in middle-aged and older individuals treated with incretin mimetics[9](https://www.nature.com/articles/s41591-026-04752-5#ref-CR9 "Locatelli, J. C. et al. Incretin-based weight loss pharmacotherapy: can resistance exercise optimize changes in body composition? Diabetes Care 47, 1718–1730 \(2024\)."). To mitigate skeletal muscle losses, the effects of muscle-preserving drugs are being tested in the setting of incretin mimetic therapy for obesity[13](https://www.nature.com/articles/s41591-026-04752-5#ref-CR13 "Heymsfield, S. B. et al. Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial. Nat. Med. 32, 869–882 \(2026\)."),[14](https://www.nature.com/articles/s41591-026-04752-5#ref-CR14 "Pratley, R. E. et al. Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial. Nat. Med. 32, 2673–2678 \(2026\)."). However, such approaches overlook a readily available non-pharmacological intervention, which is safe and potentially efficacious. Compared to other exercise modalities, resistance exercise training consistently results in greater gains in lean soft tissue mass and muscle strength while eliciting similar reductions in fat mass[15](https://www.nature.com/articles/s41591-026-04752-5#ref-CR15 "Garber, C. E. et al. American College of Sports Medicine position stand. Quantity and quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently healthy adults: guidance for prescribing exercise. Med. Sci. Sports Exerc. 43, 1334–1359 \(2011\)."). After weight loss induced by energy restriction, a combination of liraglutide and aerobic exercise training improved body composition[16](https://www.nature.com/articles/s41591-026-04752-5#ref-CR16 "Lundgren, J. R. et al. Healthy weight loss maintenance with exercise, liraglutide, or both combined. N. Engl. J. Med. 384, 1719–1730 \(2021\)."), but the effect of combining resistance exercise training with newer and more potent incretin mimetics has not been tested as a primary strategy to optimize muscle mass and strength from the outset of weight loss. We aimed to test the hypothesis that, in adults with overweight or obesity, adding resistance exercise to tirzepatide treatment would attenuate losses in lean soft tissue mass compared to tirzepatide without resistance training, using DXA to assess changes in body composition. We also sought to test a second hypothesis: that this combination would improve regional muscle strength compared to tirzepatide without resistance exercise. Additional related secondary outcomes examined included changes in cardiovascular risk factors. ## Results ### Trial design Participants who were obese, or overweight with ≥1 weight-related comorbidities, were randomized to resistance exercise training or usual activities in parallel groups with background tirzepatide therapy for 40 weeks. Co-primary endpoints were changes in fat mass and lean soft tissue mass. Secondary outcomes included regional muscle strength and cardiovascular risk factors (reported here) and
## Related Clinical Research

- [GLP-1 receptor agonists and PMOS: evidence, mechanisms, and who may benefit](https://medichelpline.com/clinical-feed/medical-news-today-0-can-glp-1s-really-help-treat-pmos-experts-answer-3-key-questions.md)
- [Undiagnosed type 2 diabetes presenting as DKA with hypertriglyceridemia-induced acute pancreatitis](https://medichelpline.com/clinical-feed/cmaj-1-undiagnosed-type-2-diabetes-presenting-as-diabetic-ketoacidosis-with.md)
- [No Patient Left Behind: Expanding Semaglutide’s Reach](https://medichelpline.com/clinical-feed/endocrine-news-21-no-patient-left-behind-expanding-semaglutide-s-reach.md)
- [Beyond the Scale: What Else Glucagon-like Peptide-1 Receptor Agonists Can Do](https://medichelpline.com/clinical-feed/endocrine-news-34-beyond-the-scale-what-else-glucagon-like-peptide-1-receptor-agonists-can-do.md)
- [Tirzepatide in Older Adults with Type 2 Diabetes: Real-World Hypoglycemia and Weight Outcomes](https://medichelpline.com/clinical-feed/pubmed-42457543.md) (DOI: 10.1507/endocrj.EJ26-0246)

## Navigation
- [← Back to Endocrinology Feed](https://medichelpline.com/clinical-feed/endocrinology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.